Our study is the first to show DNA methylation of the ABCB1 CpG island to be associated with ERBB2 amplification, TP53 mutation status, and response to doxorubicin treatment and overall survival in a doxorubicin-exposed cohort of primary breast cancers. The gene discussed is TP53; the disease is breast cancer.